Press Release
Dimension Bio and winners of the Chicago Innovation Awards Ring the Nasdaq Closing Bell
CHICAGO, Illinois, USA – August 1, 2025 – Dimension Bio, a biotechnology company pioneering regenerative therapeutics, joined fellow winners of the Chicago Innovation Awards, the Chicago region’s foremost annual celebration of innovation, in New York City on Friday, August 1st to ring the Closing Bell of the Nasdaq Stock Market. The event emphasizes the surge of innovation that is occurring in the Chicago region, and shines a spotlight on the organizations that make up its vibrant economy.
“Chicago Innovation Award winners cut across all industries and represent the best in new product and service development from large companies, startups and non-profits,” said Luke Tanen, President and CEO of Chicago Innovation. “Their winning innovations are solving a range of unmet needs in the marketplace, and we’re proud to celebrate their successes on a global stage by ringing the Nasdaq Bell.”
Joining Dimension Bio were other winners of the 2024 Chicago Innovation Awards. The full list of 2024 winners includes Abbott, Ascent Integrated Tech, the Center for Advancing Safety of Machine Intelligence, Chicago Chefs Cook, Cook County Manufacturing Reinvented, DeVry University, Dimension Bio, Disability Lead, Feeding America, First Women’s Bank, HDVI, LanzaJet, Medline, OpenMarkets, Rapunzl, REACH Pathways, Rush University System for Health, Springrose, The African American Heritage Water Trail, True Star Media, United Way of Metro Chicago and Valent BioSciences.
“Ringing the Nasdaq bell alongside fellow Chicago innovators is a powerful reminder of what happens when science, engineering, and an unwavering focus on patients converge,” said Caralynn Nowinski Collens, M.D., Co-Founder, and Chief Executive Officer of Dimension Bio. “From our roots in Chicago’s vibrant ecosystem, we’ve advanced BioNidum™ - a cell-delivery system that gives therapeutic cells a true home inside the body. This recognition underscores the progress we’re making toward bringing durable, organ-restoring therapies to patients.”
Dimension Bio is unlocking the next generation of regenerative medicine with its proprietary BioNidum™ system that overcomes key limitations in cell therapy delivery. Their lead program harnesses this technology to treat patients with liver failure by creating a tissue therapeutic that offers immediate and durable hepatic function – bridging patients through the acute crisis to recovery or transplant.
For more information about Dimension Bio and its leadership team, please visit www.dimension.bio.
Media Contact: Cole Johnson, SVP Corporate Development, Dimension Bio, cole@dimension.bio
+ About Dimension Bio
Dimension Bio is a biotechnology company pioneering regenerative therapeutics. We design lifesaving solutions that restore organ function lost to disease, trauma or aging. Our bioinspired cell delivery system, BioNidum™, fuses materials science, 3D-printing, and digital manufacturing to transform cells into implantable, tissue-like therapies.
By providing a three-dimensional architecture that promotes rapid vascularization and seamless tissue integration, our tissue therapeutics create the conditions cells need to survive, function, and persist. The result is a more durable and effective therapeutic response—unlocking the curative potential of cell therapies.
Our lead program targets liver failure, providing immediate supplemental liver function to stabilize patients in crisis. By enabling the native liver to recover, it offers an alternative to transplant and fills a critical gap for those with limited treatment options.